ACELRX PHARMACEUTICALS WKN: A1H64B ISIN: US00444T1007 Kürzel: R5X Forum: Aktien Thema: Hauptdiskussion

Da kommt jetzt eine Prognose vom großen und mit einem Kauf bewertet. Kursziel 9$ Der Kurs wird aber wieder runter gedrückt. Habe zeit genug und glaube sogar an Kurse wie 10-12 Euro in den nächsten 2 Jahren.

Mal sehen, was am Ende des Tages dann übrig bleibt.

Bisher keine wirklichen news entdeckt und bei stocktwits freut man sich über den Beitrag: https://www.tipranks.com/news/article/these-2-penny-stocks-could-surge-over-300-say-analysts/

Gibt es news

Was da los

Mal spontan 30% nach oben geschossen... 🍀

AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA https://www.streetinsider.com/dr/news.php?id=17704359&gfv=1

AcelRx Announces $10 Million Registered Direct Common Stock Offering https://www.prnewswire.com/news-releases/acelrx-announces-10-million-registered-direct-common-stock-offering-301190326.html ...today announced it has entered into an agreement with three life sciences-focused investment funds that are existing investors and new investors in AcelRx, for the sale of 8,333,333 shares of common stock at $1.20 per share. AcelRx estimates gross proceeds from the offering of approximately $10.0 million.  The closing of the transaction is expected to occur by December 11, 2020, subject to satisfaction of customary closing conditions. ...

AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-partnership-with-the-national-rural-health-association-301186465.html

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-commentary-in-practical-pain-management-on-previously-published-clinical-data-on-preoperative-administration-of-dsuvia-301175809.html

Zahlen nicht gut schade

AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-third-quarter-2020-financial-results-301167437.html Third quarter product sales of $1.3M, up significantly compared to $0.3M in the second quarter The Zimmer Biomet collaboration, addition of DSUVIA to the U.S. Department of Defense Joint Deployment Formulary and the U.S. Army contract highlight third quarter achievements and growth opportunities ...

Da sind sie wieder die leerverkäufer

Wieder sehr erfreulich heute 📈🍀

Wichtig ist das sie nächste Woche den Trend beibehaltet

Viel fehlt nicht mehr.